Tekturna HCT approved for first-line hypertension therapy

The FDA has approved an expanded indication for Tekturna HCT (aliskiren/hydrochlorothiazide tablets, from Novartis) to include initial therapy for patients with hypertension who are likely to need multiple drugs to achieve their blood pressure goals. This approval was based on clinical trial data involving more than 2,700 patients, which showed that treatment with Tekturna and hydrochlorothiazide (HCTZ) offered greater blood pressure reductions than either drug alone.

Tekturna HCT is a combination direct renin inhibitor plus thiazide diuretic. It is available in four fixed-dose combination tablets containing aliskiren and HCTZ: 150mg/12.5mg, 150mg/25mg, 300mg/12.5mg, and 300mg/25mg.

For more information call (888) 669-6682 or visit www.tekturna.com.